

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Hu CD3 BUV805 SK7 100Tst

RRID:AB_2870181

Type: Antibody

Proper Citation

BD Biosciences Cat# 612893, RRID:AB_2870181

Antibody Information

URL: http://antibodyregistry.org/AB_2870181

Proper Citation: BD Biosciences Cat# 612893, RRID:AB_2870181

Target Antigen: CD3

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Flow - Surface

Antibody Name: Hu CD3 BUV805 SK7 100Tst

Description: This monoclonal targets CD3

Target Organism: Human

Clone ID: clone SK7 (also known as Leu-4)

Antibody ID: AB_2870181

Vendor: BD Biosciences

Catalog Number: 612893

Record Creation Time: 20250820T050859+0000

Record Last Update: 20250820T205544+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD3 BUV805 SK7 100Tst.

No alerts have been found for Hu CD3 BUV805 SK7 100Tst.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Isogawa M, et al. (2025) Antibody durability is influenced by interleukin-2 production by undifferentiated memory T helper cells and extensive B cell clonal expansion. *Cell reports*, 44(7), 115934.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. *Cell reports methods*, 5(5), 101049.

Galvez-Cancino F, et al. (2025) Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. *Immunity*, 58(5), 1236.

Zhang W, et al. (2025) Identification of antigen-specific functional CD8+ T cells using an optofluidic system independent of epitope information. *iScience*, 28(10), 113600.

Lindner S, et al. (2024) Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. *Nature microbiology*, 9(3), 614.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. *Cell reports methods*, 3(1), 100388.

Koutsakos M, et al. (2023) SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. *Immunity*, 56(4), 879.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Burkard T, et al. (2022) Differential expression of CD8 defines phenotypically distinct cytotoxic T cells in cancer and multiple sclerosis. *Clinical and translational medicine*, 12(12), e1068.

Au L, et al. (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer cell*, 39(11), 1497.

Mold JE, et al. (2021) Divergent clonal differentiation trajectories establish CD8+ memory T cell heterogeneity during acute viral infections in humans. *Cell reports*, 35(8), 109174.